Диссертация (1174213), страница 44
Текст из файла (страница 44)
– 2017. - №7(1). – Р.60-84. doi: 10.21037/cdt.2016.08.10.239. KimmelSE. A pharmacogenetic versus a clinical algorithm forwarfarin dosing /KimmelSE, FrenchB, KasnerSE, JohnsonJA, AndersonJL,GageBF, RosenbergYD, EbyCS, MadiganRA, McBaneRB, Abdel-RahmanSZ,StevensSM, YaleS, MohlerER 3rd, FangMC, ShahV, HorensteinRB, LimdiNA,MuldowneyJA 3rd, GujralJ, DelafontaineP, DesnickRJ, OrtelTL, BillettHH,PendletonRC, GellerNL, HalperinJL, GoldhaberSZ, CaldwellMD, CaliffRM,EllenbergJH; COAGInvestigators // New Engl J Med. – 2013. - №369(24). –Р.2283-93.240. Kirchhof P.
Management of atrial fibrillation in seven Europeancountries after the publication of the 2010 ESC Guidelines on atrial fibrillation:primary results of the PREvention oF thromboemolic events—European Registryin Atrial Fibrillation (PREFER in AF) /Kirchhof P, Ammentorp B, Darius H, DeCaterina R, Le Heuzey JY, Schilling RJ, Schmitt J, Zamorano JL // Europace. 2014. - №16. – Р.6–14.241.
Kirchhof P. Outcome parameters for trials in atrial fibrillation:executive summary. Recommendations from a consensus conference organized bythe German Atrial Fibrillation Competence NETwork (AFNET) and the European258Heart Rhythm Association (EHRA) /Kirchhof P, Auricchio A, Bax J, Crijns H,Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, KuckKH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, SvernhageE, Tijssen J, Vincent A, Breithardt G// Eur Heart J.
– 2007. - №28. – Р.2803–2817.242. Kirchhof P. Early and comprehensive management of atrial fibrillation:executive summary of the proceedings from the 2nd AFNET-EHRA consensusconference ‘Research perspectives in AF’ /Kirchhof P, Bax J, BlomstromLundquist C, et al. // Eur Heart J. – 2009. - №30. –Р. p2969–2977c.243. Kirchhof P.
2016 ESC Guidelines for the management of atrialfibrillation developed in collaboration with EACTS: The Task Force for themanagement of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart RhythmAssociation (EHRA) of the ESC Endorsed by the European Stroke Organisation(ESO) /Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, CastellaM, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J,Popescu BA, Schotten U, Van Putte B, Vardas P; Authors/Task Force Members.;Document Reviewers // Eur Heart J. – 2016.
- №37(38). – Р.2893-2962.DOI:10.1093/eurheartj/ehw210244. Kirley K. National trends in oral anticoagulant use in the United States,2007–2011 /Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC// Circulation Cardiovascular quality and outcomes. – 2012. - №5(5). – Р.615-621.doi:10.1161/CIRCOUTCOMES.112.967299.245. Kjellgren KI. Hypertensive patients' knowledge of high bloodpressure /Kjellgren KI, Svensson S, Ahlner J, Saljo R // Scand J Prim Health Care.– 1997. -№ 15 (4). – Р.
188–92.246. Knecht S. Atrial fibrillation in stroke-free patients is associated withmemory impairment and hippocampal atrophy /Knecht S, Oelschlager C, DuningT, et al. // Eur Heart J. – 2008. - №29. – Р.2125–2132.247. Koga M. Higher Risk of Ischemic Events in Secondary Prevention forPatients With Persistent Than Those With Paroxysmal Atrial Fibrillation /Koga M,Yoshimura S, Hasegawa Y, Shibuya S, Ito Y, Matsuoka H, Takamatsu K,Nishiyama K, Todo K, Kimura K, Furui E, Terasaki T, Shiokawa Y, Kamiyama K,Takizawa S, Okuda S, Okada Y, Kameda T, Nagakane Y, Yagita Y, Kario K,Shiozawa M, Sato S, Yamagami H, Arihiro S, Toyoda K; SAMURAI StudyInvestigators//Stroke.– 2016.- №47(10).– Р.2582-8.doi:10.1161/STROKEAHA.116.013746.248.
Kooiman J. Incidence of chronic kidney disease in patients with atrialfibrillation and its relevance for prescribing new oral antithrombotic drugs/Kooiman J, van de Peppel WR, van der Meer FJ, Huisman MV // J ThrombHaemost. – 2011. - №9. – Р.1652-3.249. Kornej J. Comparison of CHADS2, R2CHADS2, and CHA2DS2VASc scores for the prediction of rhythm outcomes after catheter ablation of atrialfibrillation: the Leipzig Heart Center AF Ablation Registry /Kornej J, Hindricks G,Kosiuk J, et al.
//Circ Arrhythm Electrophysiol. – 2014. - №7. – Р.281–7.259250. Kotecha D. Atrial fibrillation and heart failure due to reduced versuspreserved ejection fraction: A systematic review and meta-analysis of death andadverse outcomes /Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY // IntJ Cardiol. – 2016. - №203. – Р.660–666.251. Kotecha D. Atrial fibrillation in heart failure: what should we do?/Kotecha D, Piccini JP // Eur Heart J. – 2015.
- №36. – Р.3250–3257.252. Lane DA. Best practice for atrial fibrillation patient education /LaneDA, Barker RV, Lip GY // Curr Pharm Des. – 2015. - №21. – Р.533–43.253. Lara-Vaca S. The Mexican Registry of Atrial Fibrillation (ReMeFa)/Lara-Vaca S, Cordero-Cabra A, Martínez-Flores E, Iturralde-Torres P // Gac MedMex. – 2014.
- №150 Suppl 1. – Р.48-59.254. Larsen TB. Efficacy and safety of dabigatran etexilate and warfarin in“real-world” patients with atrial fibrillation: a prospective nationwide cohort study/Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M et al. //J Am Coll Cardiol. – 2013. - №61. – Р.2264–73.255. Leonardi-Bee J. Blood pressure and clinical outcomes in theInternational Stroke Trial /Leonardi-BeeJ, Bath PMW, Phillips, SJ et al. //Stroke. 2002.
- №33. - Р. 1315-1320.256. Lévy S. Characterization of different subsets of atrial fibrillation ingeneral practice in France: the ALFA study /Lévy S, Maarek M, Coumel P et al.//Circulation. – 1999. - № 99. - P. 3028-3035.257. Liard F. Atrial fibrillation and anticoagulation: general practitioner,cardiologist and patient's points of view /Liard F, Le Heuzey J, Aliot E et al.
//Presse Med. – 2013. - №42(7–8). – Р. 259–70.258. Lindgren P. Economic evaluation of ASCOT-BPLA: antihypertensivetreatment with an amlodipine-based regimen is cost effective compared with anatenolol-based regimen /Lindgren P, Buxton M, Kahan T et al. on behalf of theASCOT trial investigators // Heart. – 2008. - №94 (2). – Р. e4.259. Lindgren P. Utility loss and indirect costs following cardiovascularevents in hypertensive patients: the ASCOT health economic substudy /LindgrenP, Kahan T, Poulter N et al., on behalf of the ASCOT investigators // Eur J HealthEcon.
– 2007. - №8 (1). – Р. 25–30.260. Lip G. Inappropriate utilization of anticoagulation in patients withatrial fibrillation: the global anticoagulant registry in the field (GARFIELD)registry /Lip G, Bassand J-P, Fitzmaurice D, Goldhaber S, Goto S, Verheugt S,Turpie A, Mueller I, Rushton-Smith S, Kakkar A // J Am Coll Cardiol. – 2012. №59(13s1). – Р.E670—E670.261. Lip GY. Contemporary management of atrial fibrillation: what canclinical registries tell us about stroke prevention and current therapeuticapproaches? /Lip GY, Al-Khatib SM, Cosio FG, Banerjee A, Savelieva I, Ruskin J,Blendea D, Nattel S, De Bono J, Conroy JM, Hess PL, Guasch E, Halperin JL,Kirchhof P, Cosio MD, Camm AJ // J Am Heart Assoc.
– 2014. - №3(4). doi:10.1161/JAHA.114.001179.260262. Lip GY. Relationship of the SAMe-TT(2)R(2) score to poor-qualityanticoagulation, stroke, clinically relevant bleeding, and mortality in patients withatrial fibrillation /Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L // Chest. –2014. - №146. –Р.719–726.263. Lip GY. A prospective survey in European Society of Cardiologymember countries of atrial fibrillation management: baseline results ofEURObservational Research Programme Atrial Fibrillation (EORP-AF) PilotGeneral Registry /Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, RasmussenLH, Oliveira MM, Mairesse G, Crijns HJGM, Simantirakis E, Atar D, Kirchhof P,Vardas P, Tavazzi L, Maggioni AP // Europace.
– 2014. - №16 (3). – Р. 308-319264. Lip GY. Prognosis and treatment of atrial fibrillation patients byEuropean cardiologists: one year follow-up of the EURObservational ResearchProgramme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilotregistry) /Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L,Petrescu L, Darabantiu D, Crijns HJ, Kirchhof P, Vardas P, Tavazzi L, MaggioniAP, Boriani G // Eur Heart J. – 2014. - №35. – Р.3365–3376.265.
Lip GY. Improved outcomes with European Society of Cardiologyguideline-adherent antithrombotic treatment in high-risk patients with atrialfibrillation: a report from the EORP-AF General Pilot Registry /Lip GY, LarocheC, Popesru MI, Rasmussen LH, et al. // Europace.
- 2015. - №17(12). – Р.1777-86doi:10.1093/eurpoace/euv269.266. Lip GY. Refining clinical risk stratification for predicting stroke andthromboembolism in atrial fibrillation using a novel risk factor-based approach: theEuro Heart Survey on atrial fibrillation /Lip GY, Nieuwlaat R, Pisters R, et al. //Chest. – 2010. - № 137. – Р.
263–272.267. Lip GY. 'Real-world' antithrombotic treatment in atrial fibrillation: TheEORP-AF pilot survey /Lip GY, Laroche C, Dan GA, Santini M, KalarusZ, Rasmussen LH, Ioachim PM,TicaO,Boriani G,Cimaglia P,DiembergerI,HellumCF,Mortensen B, Maggioni AP // Am J Med. – 2014. - №127(6). – Р.519-29.e1.doi: 10.1016/j.amjmed.2013.12.022.268. Lloyd-Jones DM. Lifetime risk for development of atrial fibrillation:the Framingham Heart Study /Lloyd-Jones DM, Wang TJ, Leip EP et al. //Circulation. - 2004. - №110.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
